Despite Vyvanse's loss of exclusivity, Takeda treads water thanks to launch momentum

Despite the recent loss of exclusivity on Takeda's attention-deficit/hyperactivity disorder (ADHD) heavy hitter Vyvanse, the company's portfolio of newer products continues to hold the sales line.